Alemtuzumab Archive - MS-Docblog

Lemtrada – what’s next?

6. March 2020 Prof. Dr. med. Mathias Mäurer Therapy for MS

During the past year, the MS drug Lemtrada was reviewed by the European Medicines Agency (EMA) for its benefit-risk ratio. The basis for this so-called §20 procedure were reports of serious side effects, in some

That was 2019 …

20. December 2019 Prof. Dr. med. Mathias Mäurer General

The year is coming to an end. Also in 2019, there were many interesting news for MS patients, which I also partly commented on in this blog. In my opinion, nothing really groundbreaking has happened.

Evaluation of the Benefit-Risk Ratio of Alemtuzumab (Lemtrada)

12. July 2019 Prof. Dr. med. Mathias Mäurer Therapy for MS

Many of you may have noticed, but especially patients who have been treated with Lemtrada, are concerned that the European Medicines Agency (EMA) initiated a safety procedure on April 11, 2019 to assess the benefit-risk

Monitoring under Alemtuzumab is essential …

22. November 2017 Prof. Dr. med. Mathias Mäurer Therapy for MS

Currently, a report on a death due to a cerebellar hemorrhage after administration of the MS drug Alemtuzumab is causing attention. The case occurred back in December 2016 and was known for a long time

Tysabri – what comes after?

25. June 2015 Prof. Dr. med. Mathias Mäurer Therapy for MS

The problem that arises after two years of therapy with Natalizumab (Tysabri®) I had already described in a previous blog post: After two years of therapy, the risk of progressive multifocal leukoencephalopathy (PML) increases for

Lemtrada

8. May 2015 Prof. Dr. med. Mathias Mäurer Therapy for MS

For more than a year, the monoclonal antibody Lemtrada® (Alemtuzumab) has been approved in Germany for the treatment of relapsing MS. Although the study data indicates it is a very effective MS therapy, the drug

MS Therapy 2015 – Expectations and Possibilities

2. April 2015 Prof. Dr. med. Mathias Mäurer Therapy for MS

Our opportunities in MS therapy have changed and improved significantly over the last 20 years. In the 90s of the last century, the goal of administering MS drugs was to delay the natural course of

Tag: Alemtuzumab

Lemtrada – what’s next?

That was 2019 …

Evaluation of the Benefit-Risk Ratio of Alemtuzumab (Lemtrada)

Monitoring under Alemtuzumab is essential …

Tysabri – what comes after?

Lemtrada

MS Therapy 2015 – Expectations and Possibilities

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community